Pharmafile Logo
Pharmafocus logo
Advanced Search

Xalkori

Showing 15 posts of 18 posts found.

takeda_usa_pharmaceuticals_u

Takeda’s Alunbrig topples Pfizer’s Xalkori in ALK-positive lung cancer

July 27, 2018
Medical Communications, Research and Development Alunbrig, Cancer, NSCLC, Pfizer, Takeda, Xalkori, lung cancer, pharma

Takeda has unveiled new Phase 3 data showing that its tyrosine kinase inhibitor (TKI) Alunbrig (brigatinib) not only met its …

News

Roche’s Alecensa secures NICE approval in NSCLC after topping Pfizer’s Xalkori

June 28, 2018
Sales and Marketing Alecensa, NICE, NSCLC, Pfizer, Xalkori, pharma

UK health watchdog NICE has given its approval for Roche’s selective ALK inhibitor Alecensa (alectinib) for use on the NHS, …

News
pfizer-building-logo1web

Pfizer’s Xalkori sees rejection at the hands of NICE in lung cancer

January 19, 2018
Medical Communications, Sales and Marketing Cancer, NCIE, NSCLC, Pfizer, UK, Xalkori, lung cancer, pharma

UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the …

News

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …

News
pfizer_chrome_plate

Pfizer nabs EU approval for Xalkori for certain lung cancers

August 31, 2016
Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer

The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …

News

Pfizer’s Xalkori price drop secures NICE recommendation

August 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …

News
Xalkori

Pfizer lung cancer treatment gets expanded EU approval

December 1, 2015
Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer

Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …

News
Pfizer image

Two oncology successes for Pfizer

April 22, 2015
Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology

Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …

News
xalkori

Merck and Pfizer to co-promote cancer drug

April 9, 2015
Research and Development, Sales and Marketing Cancer, Merck, Merck KGaA, NSCLC, Pfizer, Xalkori, non-small cell lung cancer, oncology

Merck KgaA and Pfizer have agreed to co-promote the latter’s lung cancer treatment Xalkori, and form a new alliance that …

News
Pfizer Xalkori

US rivals Pfizer and Merck team up for lung cancer

August 27, 2014
Medical Communications, Research and Development, Sales and Marketing Merck, NSCLC, Roche, Xalkori, melanoma, pembrolizumab

The two biggest rival US pharma firms have joined forces to help develop a new combination treatment for certain non-small …

News
Roche image

Roche lung cancer drug sees first approval

July 4, 2014
Sales and Marketing ALK+, Cancer, NSCLC, Pfizer, Roche, Xalkori, alectinib, alk, zykadia

Roche has seen the first approval for its new lung cancer drug alectinib in Japan as it looks to compete …

News
Xalkori image

Pfizer’s Xalkori impresses in new setting

March 26, 2014
Research and Development, Sales and Marketing NHS, NICE, NSCLC, Pfizer, Xalkori, lung cancer

Pfizer’s lung cancer treatment Xalkori has proven better at treating patients in a first-line setting when compared to chemotherapy. This …

News

Cancer drugs lift Pfizer in third quarter

October 30, 2013
Sales and Marketing Lipitor, Lyrica, Pfizer, Q3, Xalkori

Pfizer saw a drop in revenue for the third quarter but the future looks bright as new products begin to …

News
Xalkori image

NICE: final ‘no’ for Xalkori

September 25, 2013
Sales and Marketing NICE, NSCLC, Pfizer, Xalkori

Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …

News
xalkori image

Price cut not enough for Pfizer’s Xalkori

August 16, 2013
Sales and Marketing NICE, Pfizer, Xalkori, lung cancer

In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023